MRC1 and cancer: For example, we identified several patients with germline P/LP TP53 or MMR gene variants with no clinically reported CPS; the former would benefit from lifetime monitoring for early detection of secondary cancers as is routine for patients with LFS, and the latter could receive immunotherapies given the prevalence of chemoresistant tumors49.